Biosimilars vs. Interchangeable Biological Products: FDA Fact Check
XTalks
FEBRUARY 8, 2021
As a subset of biosimilars, interchangeable biological products can be substituted for the reference product at the pharmacy level, without the input of the prescribing physician. Unlike small-molecule generic drugs, biosimilars do not need to demonstrate bioequivalence to the innovator product.
78 
Let's personalize your content